AR Holdings Claims Par Pharma Infringed Gout Drug Patent
AR Holding maintains that Woodcliff Lake, N.J.-based Par has submitted an abbreviated new drug application to the Food and Drug Administration seeking to market a 0.6 mg oral tablet generic version of the brand name gout drug Colcrys, before its patent rights covering the medication expire.
At issue are U.S. Patents No....
To view the full article, register now.